Tuberculosis and beta-lactam antibiotics.
Mehmet Akif GunBülent BozdoğanAhmet Yilmaz CobanPublished in: Future microbiology (2020)
Tuberculosis (TB) is one of the oldest health problems in the world and it remains unresolved. Multidrug-resistant-TB and extensively resistant-TB are a serious problem for control programs. The evaluation of available antibiotics has gained importance in recent years for the treatment of resistant TB. Beta-lactam antibiotics inhibit cell wall biosynthesis in the bacteria; the presence of beta-lactamase enzyme in TB bacilli raises the question of whether this group of antibiotics can be used in treatment. As a result, it has been reported that the combination of beta-lactam antibiotics with beta-lactamase is effective against Mycobacterium tuberculosis both in vitro and in vivo. The aim of this article is to review and discuss up-to-date knowledge and future perspective on beta-lactam antibiotics and TB.
Keyphrases
- mycobacterium tuberculosis
- gram negative
- multidrug resistant
- pulmonary tuberculosis
- cell wall
- healthcare
- public health
- escherichia coli
- drug resistant
- acinetobacter baumannii
- klebsiella pneumoniae
- mental health
- social media
- climate change
- hepatitis c virus
- hiv aids
- combination therapy
- adverse drug
- drug induced
- replacement therapy